Goldman Sachs Group Inc. raised its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 415.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 816,343 shares of the company’s stock after purchasing an additional 658,069 shares during the period. Goldman Sachs Group Inc. owned 1.91% of 4D Molecular Therapeutics worth $16,539,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of FDMT. RA Capital Management L.P. raised its holdings in 4D Molecular Therapeutics by 35.6% during the 3rd quarter. RA Capital Management L.P. now owns 4,163,211 shares of the company’s stock valued at $52,998,000 after buying an additional 1,093,680 shares during the period. Vontobel Holding Ltd. bought a new stake in shares of 4D Molecular Therapeutics in the 4th quarter worth about $2,887,000. Sectoral Asset Management Inc. purchased a new position in shares of 4D Molecular Therapeutics during the 4th quarter worth about $2,887,000. DekaBank Deutsche Girozentrale bought a new position in 4D Molecular Therapeutics during the 4th quarter valued at about $966,000. Finally, Trexquant Investment LP purchased a new stake in 4D Molecular Therapeutics in the 3rd quarter worth about $566,000. 99.27% of the stock is owned by institutional investors.
Insider Activity at 4D Molecular Therapeutics
In other 4D Molecular Therapeutics news, insider Scott Bizily sold 1,750 shares of the business’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $25.74, for a total value of $45,045.00. Following the completion of the transaction, the insider now directly owns 1,737 shares in the company, valued at $44,710.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other 4D Molecular Therapeutics news, insider Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $25.74, for a total value of $45,045.00. Following the transaction, the insider now directly owns 1,737 shares of the company’s stock, valued at $44,710.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David Kirn sold 12,930 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $23.10, for a total value of $298,683.00. Following the sale, the chief executive officer now owns 1,059,153 shares of the company’s stock, valued at approximately $24,466,434.30. The disclosure for this sale can be found here. Insiders have sold a total of 24,583 shares of company stock valued at $647,368 over the last quarter. 7.30% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on FDMT
4D Molecular Therapeutics Stock Performance
Shares of FDMT opened at $20.93 on Friday. The company has a 50 day moving average price of $24.51 and a 200-day moving average price of $24.61. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $9.44 and a fifty-two week high of $36.25. The stock has a market capitalization of $1.08 billion, a PE ratio of -8.58 and a beta of 2.89.
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.07. 4D Molecular Therapeutics had a negative return on equity of 26.75% and a negative net margin of 436.30%. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $1.44 million. Equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.98 EPS for the current year.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Featured Stories
- Five stocks we like better than 4D Molecular Therapeutics
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- The 3 Best Retail Stocks to Shop for in August
- Progress Software Stock Back in the Green After Beating Forecasts
- What is the Shanghai Stock Exchange Composite Index?
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Want to see what other hedge funds are holding FDMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report).
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.